I have recently been awarded France’s national order of merit, for my career, in science, in open source, and around AI. The speech that I gave carries messages important to me (French below;...

Background Weight gain after starting antihypertensive medications is a frequent concern for patients, but there is limited data on expected weight change after initiation of these medications. A comparative effectiveness trial to evaluate this outcome would not be feasible. Objective To estimate and compare average weight change under initiating and adhering to commonly prescribed, first-line antihypertensive medications as monotherapy by emulating a target trial. Design Retrospective observational cohort study over 24 months of follow-up using electronic health records (EHR). Participants 141,260 patients prescribed one of seven antihypertensives between 2010 and 2019 across 8 US health systems. Main Outcome and Measures We examined mean weight change associated with initiation of and adherence to amlodipine, atenolol, hydrochlorothiazide, losartan, metoprolol, or propranolol, relative to lisinopril, at 6, 12, and 24 months after initiation. To adjust for baseline confounding and informative outcome measurement, we used inverse probability weighting with repeated outcome marginal structural models. Key Results After baseline and time-varying covariate adjustment, initiation of and adherence to lisinopril were associated with mean weight loss at 6 months (− 0.69 kg, 95% CI − 0.92, − 0.47), 12 months (− 0.58 kg, 95% CI − 1.05, − 0.30), and 24 months (− 1.121 kg, 95% CI − 2.013, − 0.46). Compared to lisinopril, the estimated 6-month weight change was higher for patients prescribed hydrochlorothiazide (0.68 kg, 95% CI 0.31, 1.04), losartan (0.54 kg, 95% CI 0.17, 0.93), metoprolol (1.38 kg, 95% CI 0.95, 1.76), and propranolol (1.03 kg, 95% CI 0.346, 1.62). At 12 months, metoprolol (1.74 kg, 95% CI 1.03, 2.41) and propranolol (1.72 kg, 95% CI 0.06, 3.235) continued to show higher weight change compared to lisinopril. Conclusion We observed small differences in weight change across antihypertensive medications, with lisinopril leading to weight loss and metoprolol and propranolol to modest weight gain. Clinicians should consider potential weight gain when selecting antihypertensive medications.

Research could offer hope for ME patients – but some experts urge caution and say more studies needed

Shadow justice secretary criticised for suggesting he could tell how integrated Handsworth was based on short visit

The UTS Governance Project is an independent, staff-led initiative to strengthen transparency, accountability and participation in how our university is run. Inspired by the ANU Governance Project, ...

Proceedings of the 10th Machine Learning for Healthcare Conference Held in Mayo Clinic, Rochester, MN, USA on 15-16 August 2025 Published as Volume 298 by the Proceedings of Machine Learning Research ...

Writing is a critical skill for modern science, enabling collaboration, scientific discourse, public outreach, and more. Accordingly, it is important to consider how physicists and astronomers are tra...

The Australia Institute has released its audited analysis of ANU’s 2023 and 2024 budget. ANU’s unaudited deficit was reported at $142.5 million, while its audited revenue showed a surplus of $89.9 mil...

We talk to Evan You about Vite's journey from a prototype inspired by ES Modules to the industry-standard build tool. Also: Vite+ and AI.

By making the world’s microbial DNA easier to explore, LexicMap helps researchers track outbreaks, study antibiotic resistance, and understand microbial diversity.

We acknowledge the traditional owners of the lands on which TAFE SA stands.